The role of surgery in the management of patients with platinum-sensitive recurrent ovarian cancer: Survey among Dutch gynecologists and medical oncologists

Rafli van de Laar*, Petra L. M. Zusterzeel, Toon Van Gorp, Petronella B. Ottevanger, Leon F. A. G. Massuger, Roy F. P. M. Kruitwagen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Web of Science)


Objective. Evidence of randomized comparative clinical trials on surgery in recurrent platinum-sensitive ovarian cancer is non-existing. Three randomized phase 3 trials are ongoing. The aim of this study is to evaluate the current opinion of Dutch gynecologists and medical oncologists awaiting the results of these three trials. Methods. A 16-item questionnaire was sent to all gynecologists (N = 124) and medical oncologists (N = 195) with special interest in gynecologic oncology in the Netherlands. The data were collected and analyzed using descriptive statistics. Results. In total, 80 (65.0%) gynecologists and 67 (34.0%) medical oncologists responded. Among the respondents, 113% and 26.9% were not convinced of the benefit of secondary cytoreductive surgery, respectively. For most gynecologists and medical oncologists completeness of primary surgery (74.6% and 75.5%, respectively) and performance status (100% and 98%, respectively) were important factors when considering surgery. For only about 17.5% of all respondents diagnostic laparoscopy before surgery is a prerequisite. Most respondents (81.7% and 87.8%, respectively) would use platinum-based chemotherapy with paclitaxel as their agents of choice after surgery. In general medical oncologists settle for a smaller gain in both progression free as well as overall survival than gynecologists. Conclusions. Although most gynecologists and medical oncologists are already convinced of the usefulness of secondary cytoreductive surgery in certain patients, a better understanding of the real advantages and disadvantages and patient's selection criteria for secondary cytoreductive surgery will be achieved after the completion of three ongoing randomized controlled trials (DESKTOP III, GOG 213 and the SOCceR).
Original languageEnglish
Pages (from-to)561-566
JournalGynecologic Oncology
Issue number3
Publication statusPublished - Dec 2013


  • Secondary cytoreductive surgery
  • Recurrent ovarian cancer

Cite this